Posted by Michael Wonder on 19 Jun 2018
Sandoz Canada becomes the first Canadian pharmaceutical company to enter the medical cannabis field
19 June 2018 - Sandoz Canada and Tilray finalise alliance to provide Canadians with greater access to high-quality, non-combustible medical cannabis options.
Sandoz Canada today announced that it has finalized its collaboration agreement with Tilray, a Health Canada licensed producer of medical cannabis, allowing Sandoz Canada to become the first Canadian pharmaceutical company to enter the medical cannabis field. The alliance will support the rising interest in medical cannabis1 by providing patients with medical treatment options of stringent manufacturing standards that are adapted to their medical conditions, advocating for broader access to products, and increasing product innovation, research and education.
Eight Sandoz and Tilray co-branded non-combustible medical cannabis products are currently available from Tilray through Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), including cannabis capsules and ingestible oils. Sandoz will not work in the soon-to-be legalised recreational combustible cannabis area.
